Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 3036-3043

  Freedman, Arnold ^a   Neelapu, Sattva S ^a   Nichols, Craig ^a   Robertson, Michael J ^a   Djulbegovic, Benjamin ^a   Winter, Jane N ^a   Bender, John F ^a   Gold, Daniel P ^a   Ghalie, Richard G ^a   Stewart, Morgan E ^a   Esquibel, Vanessa ^a   Hamlin, Paul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; MITUMPROTIMUT T; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; CANCER VACCINE; HEMOCYANIN; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CHILL; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; STEM CELL TRANSPLANTATION; THORAX PAIN; TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DISEASE PROGRESSION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED;

EID: 67649961713     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.8903     Document Type: Article

References (21)

1. Kwak LW, Campbell MJ, Czerwinski DK, et al: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327: 1209-1215, 1992
2. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135, 1997
3. Bendandi M, Gocke CD, Kobrin CB, et al: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171-1177, 1999
4. Redfern CH, Guthrie TH, Bessudo A, et al: Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 24:3107-3112, 2006
5. Koc ON, Redfern C, Wiernik PH, et al: Continued late conversion to complete remission (CR/CRu) and durability of remission (DUR) in pts with B-cell follicular lymphoma (FL) treated with rituximab followed by mitumprotimut-T (Id-KLH, FavId) immunotherapy. Blood 110, 2007 (abstr 3427)
6. Koc ON, Redfern C, Wiernik PH, et al: Active immunotherapy with mitumprotimut-T (Specifid, Id-KLH, FavId) following rituximab cytoreduction in patients with follicular B-cell lymphoma: Progression-free survival at 4-year follow-up - Study FavId-04. Blood 110, 2007 (abstr 2567)
7. Solal-Cé ligny P, Roy P, Colombat P, et al: Follicular Lymphoma International Prognostic Index. Blood 104:1258-1265, 2004
8. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
9. Freedman A, Hamlin PA, Neelapu S, et al: Phase III trial of active immunotherapy (FavId, Id/KLH) following rituximab induction therapy: Clinical responses in patients with follicular non-Hodgkin's lymphoma. Blood 108, 2006 (abstr 2756)
10. Koc O, Redfern C, Wiernik P, et al: Extended follow-up and analysis with central radiological review of patients receiving FavId (Id/KLH) vaccine following rituximab. Blood 106, 2005 (abstr 772)
11. Neelapu SS, Kwak LW, Kobrin CB, et al: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11:986-991, 2005
12. Stergiou AM, Neelapu SS, Casciano R, et al: BiovaxID vaccine therapy of follicular lymphoma in first remission: Phase III blinded safety update. Blood 110, 2007 (abstr 4500)
13. Levy R, Robertson MJ, Ganjoo K, et al: Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). Proc Am Assoc Cancer Res 2008 (abstr LB-204)
14. Colombat P, Brousse N, Morschhauser F, et al: Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): Survival analyses with extended follow-up of 7 years. Blood 108, 2006 (abstr 486)
15. Witzig TE, Vukov A, Habermann TM, et al: Rituximab therapy for patients with newly diagnosed, advanced-stage follicular grade I non-Hodgkin's lymphoma: A Phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23: 1103-1108, 2005
16. Ghielmini M, Hsu Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 103:4416-4423, 2004
17. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
18. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
19. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of Yttrium-90-labeled ibritumomab tioxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002
20. Inogè s S, Rodriguez-Calvillo M, Zabalegui N, et al: Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292-1301, 2006
21. Timmerman JM, Vose J, Levy R, et al: Longterm follow-up of patients treated in a Phase 2 trial with MyVax personalized immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma (NHL). Blood 106, 2005 (abstr 2438)